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Abstract
Background: In recent times, the use of health technologies in the diagnosis and treatment of diseases
experienced considerable and accelerated growth. The goal of the present study was to describe the designated
pilot MCDM (Multiple Criteria Decision Making) model for priority setting of health technology assessment in Iran.
Methods: Relevant articles were sought and retrieved from the most appropriate medical databases, including the
Cochrane Library, PubMed and Scopus via three separate search strategies, using MESH and free text until March, 2015.
Retrieved criteria were questioned from health technology assessment experts in two rounds and the relative weight
for valid criteria was finally obtained from paired wise comparison method. After extraction of relative weights based
on the aforementioned procedure, TOPSIS (The Technique for Order of Preference by Similarity to Ideal Solution)
priority setting model was designed. The stated model was applied for assessing three technologies (adenosine, tissue
plasminogen activator and mechanical thrombectomy) which were available for projects call of Iranian health
technology assessment department in order to determine applicability of the model for practical purpose.
Results: Nine criteria, including efficiency/effectiveness, safety, population size, vulnerable population size, availability of
alternative technologies, cost effectiveness in other countries, budget impact, financial protection, quality of evidence, were
extracted by the Iranian health technology assessment experts. The relative weights of these criteria were as follows 0.12, 0.2,
0.06, 0.08, 0.08, 0.13, 0.08, 0.09, and 0.15, respectively. Finally TOPSIS pilot model was designed by three health technologies
and nine criteria relative weights. Results showed that, the applicability of the stated model was suitable and as the pilot
testing, tissue plasminogen activator was the first priority, adenosine was second and mechanical thrombectomy was third
for performing health technology assessment by the Iranian ministry of health and medical education.
Conclusion: According to the results of this study, this model with nine effective criteria and their relative weights and in
combination with TOPSIS approach could be used with suitable applicability by health technology assessment department in
deputy of curative affairs and food and drug organization for determination of research priorities in health technology assessment.
Keywords: Priority setting, Health Technology Assessment, Iran
Background
Acceptance of health technologies in health systems within
the last decades has experienced some intensive changes.
The belief in abiding with the acceptance of health tech-
nologies within 1960s and 1970s gradually was replaced by
an increasing suspicion of society towards the credibility of
advanced health technologies. Nowadays, politicians and
the public have an ambiguous opinion about the use of a
new health technology [1].
Within recent years, the use of health technologies for
diagnosis and treatment of diseases experienced consider-
able and accelerated growth. The proper use of these tech-
nologies may considerably help in the diagnosis and
treatment of diseases. On the other hand, unlimited and
unrestricted entry of these technologies may result in in-
duced demand by service providers [2].
Given, the number of health technologies which re-
quired assessment was more than available resources;
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so all health technology assessment organizations
must prioritize their research projects [3]. Various
studies have been applied for this purpose worldwide
until now, such as Canadian Drug and Health Tech-
nologies Organization (CADTH) which utilized the
analytical hierarchy process (AHP) for priority setting
of health technologies [4]. Another existing model in
relation to priority and selection of health technolo-
gies was EVIDEM (Evidence and Value: Impact on
Decision Making) model in Canada [5]. Nonetheless,
there is no consensus on appropriate priority setting
between health technology assessment organizations
[3]. The main goal of the present study was to de-
scribe the designated pilot MCDM model for priority
setting of health technology assessment in Iran.
Methods
In order to achieve the aforementioned goal, relevant arti-
cles until March, 2015, based on three separate strategies
using MESH and free text were sought for using the
Cochrane Library, Pub Med and Scopus. The criteria and
sub criteria (in pre assessment and assessment phase, at this
stage, the criteria of assessment phase were also included,
on the assumption that there may be some of these criteria
which can be used in pre assessment phase in Iranian
health system context) obtained from systematic review
were questioned by experts of health technology assess-
ment context via questionnaire (these expert were selected
from official committee of HTA in Iranian ministry of
health and medical education and during of this research
just 11 ones of them were available for inclusion). At first,
to determine the content validity as pilot, experts of health
technology assessment were provided with questionnaire in
three forms, including (a.) determination of face validity for
each item (as two-options: it is clear and demonstrative or
it is not clear and demonstrative), (b.) determination of
content validity rate (CVR) for each item (as three-options:
it is necessary, useful but not necessary or not necessary)
and (c.) determination of content validity index (CVI) for
each item (as five-options: completely irrelevant, irrelevant,
relatively irrelevant, relevant or completely relevant). Sub
criteria from which the minimum content validity was ob-
tained was also included in the final questionnaire phase. In
this questionnaire, the importance of each of these sub cri-
teria was questioned by experts in these five options con-
text (very slightly important, slightly important, moderately
important, important, and very important). For this pur-
pose, a 75 % cut point was used. This implied that for each
one of these sub criteria, 75 % of experts who voted import-
ant or very important in the process of health technology
assessment priority setting were included in the analytic
hierarchy process (AHP) phase for extraction of their rela-
tive weight through paired wise comparisons. In the analyt-
ical hierarchy process, relative weight was obtained by
paired comparison matrix. For a consistent paired compari-
son matrix, weight was calculated through normalization of
elements of each column. However, if the matrix was in-
consistent, to obtain the weight, four major methods were
introduced, including 1 - least squares, 2 - least logarithm
squares, 3 - Eigen vector, 4 - approximate methods [6]. The
first three methods involve tedious calculations, thus some
approximate methods have been proposed which are of
lower accuracy (that is acceptable) and involve less and
simpler calculations. In this study, geometric mean method
was used. The geometric mean of elements of each row
was calculated; later, the obtained vector was normalized to
obtain the weight vector. Inconsistency rate of each matrix
A was calculated based on the following steps:
1. Formation of the paired comparison matrix A;
2. Specification of the weight vector (W);
3. Is the maximum Eigen value of matrix A (λmax)
specified? If yes, go to forth step, otherwise
(according to following steps) estimate its value.
3-1:Obtaining a well-suited estimation of λmaxW by
multiplying vector W by matrix A (AW= λmaxW);
3-2:Upon dividing the obtained values for λmaxW by
relative W, estimation of of λmax is calculated;
3-3:The obtained mean λmax is calculated;
4. Calculation of inconsistency index (I.I) based on
following equation:
Formula (1)
I:I ¼ λmax−n
n−1
5. Calculation of inconsistency ratio (I.R.) based on
following formula:
Formula (2)
I:R ¼ I:I
I:I:R:
In this formula I.I.R. denotes the random matrix incon-
sistency index. This matrix was calculated for matrices
whose numbers were completely randomly selected. In
each matrix, the product of dividing the inconsistency
index by random matrix inconsistency matrix with the
same dimension will be a suitable criterion for judgment
about matrix inconsistency which is called inconsistency
ratio. If this number is smaller or equal to 0.1, system
consistency is acceptable; otherwise the judgments must
be revised [6].
After extraction of relative weights based on the above
procedure, TOPSIS priority setting model was designed.
Essential principles of this method are as follows:
a. Appropriateness of each index must be uniform in
ascending (descending) order (whatever rij is higher,
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appropriateness also higher or vice versa) so that the
best existing value of an index denotes its ideal and
the worst existing value thereof shows negative ideal
for it.
b. The interval of an option from ideal (or negative
ideal) may be calculated as Euclidean distance (from
second exponent) or as the sum total of absolute
value of linear distances (known as block gaps) that
is dependent on the exchange and replacement rate
among indices.
First step: this involves the conversion of existing deci-
sion making matrix to a matrix descaled using following
formula:
Formula (3):
nij ¼ rijﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃXm
i¼1r
2
ij
q
Second step: this involves creating weighted descaled
matrix by assumption of vector W as input to the
algorithm.
Formula (4):
W ¼ w1;w2;…wnf g≈ supposed of DMð Þ
V ¼ ND: Wnn ¼
V11… V1j… V1n…
⋮ ⋮ ⋮
Vm1⋯ Vmj⋯ Vmn⋯
Where ND is a matrix having the score of indices
therein descaled and comparable and Wn× n is a diamet-
rical matrix having only its main elements as nonzero.
Third step: This involves determination of ideal solu-
tion and negative ideal solution
For ideal option A+ and negative ideal A-, the follow-
ing definition is provided:
Formula (5):
Aþ ¼
n
ðmax
i
V ij j∈Jj Þ; ðmini V ij j∈Jj Þji ¼ 1; 2;…m
o
¼ Vþ1 ;Vþ2 ;…;Vþj ;…;Vþn
n o
A‐ ¼
n
ðmin
i
V ij j∈Jj Þ; ðmaxi V ij j∈Jj Þji ¼ 1; 2;…m
o
¼ V −1 ;V −2 ;…;V −j ;…;V −n
n o
J ¼ j ¼ 1; 2;…; njjsÞ referred to the profitg
J ¼ j ¼ 1; 2;…; n js referred to the costgj
Forth step: This involves calculation of separation size
(distance).
The distance between option i and ideals based on
Euclidean method is as follows:
Formula (6)
diþ ¼
Xn
j¼1
Vij‐V
þ
j
 2( )0:5
; i ¼ 1; 2;…;m
di‐ ¼
Xn
j¼1
Vij‐V
‐
j
 2( )0:5
; i ¼ 1; 2;…;m
Fifth step: This involves calculation of relative closeness
of Ai to the ideal solution. This relative closeness is defined
as follows:
Formula (7):
cliþ ¼ di−diþ þ di−ð Þ ; 0≤cliþ≤1; i ¼ 1; 2;…;m
As observed, if
Ai ¼ A∓
Then:
diþ ¼ 0
And will have:
cliþ ¼ 1
And in case:
Ai ¼ A−
Then:
di− ¼ 0
And
cliþ ¼ 0
Therefore, whatever Ai is closer to the ideal solution A
+,
value of cli will be closer to the unit.
Sixth step: This involves ranking of the options. The
existing options of supposed problem can be ranked
based on the descending order cli + [7, 8].
Ultimately, the first designed model was examined by
pilot test using the last health technology assessment pro-
jects call of The Iranian Department of Health Technology
Assessment, including 3 technologies (Adenosine, Tissue
Plasminogen Activator (tPA), Mechanical Thrombectomy)
and the results were provided to the experts for judgment.
Results
Systematic review
After screening of retrieved papers via PRISMA frame-
work, from 7012 papers, 40 were left included in the
final phase. Criteria for selection of health technologies
(in pre-assessment and also in assessment phase) were
categorized into the six main themes such as 1 - health out-
comes, 2 - disease and target population, 3 - technology
alternatives, 4 -economic aspects, 5 - evidence and 6 - other
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Table 1 Classification of main criteria and sub criteria based on frequency in reviewed Studies (in pre-Assessment and also in Assessment phase)
Main
Criteria
Health Outcomes Disease and Target Population Alternatives Economic Aspects Evidence Other Factors
Sub criteria Frequency Sub criteria Frequency Sub criteria Frequency Sub criteria Frequency Sub criteria Frequency Sub criteria Frequency
1 Health effects/benefits 8 Disease severity 12 Number of
alternatives
2 Cost-
effectiveness
15 Quality of
evidence
4 Issues related
to health
system
11
2 Clinical effects/benefits 7 Disease burden 8 Availability of
alternative
1 Costs 11 Number of
evidence
3 Sporadic sub
criteria
11
3 Efficacy/effectiveness 4 Target population age 7 Limitations
of
comparative
interventions
1 Budget
impact
10 Evidence
relevance and
validity
1 Political, social
and moral
issues
10
4 Individual health benefits 3 Population size 3 Lack of
alternatives
1 Economic
impact
6 Power of
evidence
1 Benefits of
beneficiaries
6
5 Safety 3 Number of potential
beneficiaries
3 - - Poverty
Reduction
4 Completeness
and consistency
of reporting
evidence
1 Issues related
to patients
5
6 Quality of life 1 Characteristics of
target social groups
for intervention
2 - - Value for
money
2 Adherence to
requirements of
decision making
body
1 Issues related
to decision-
making
conditions
5
7 Potential changes in
health consequences
1 Number of patients 2 - - Financial
opportunity/
consequences
2 - - Fairness and
equity
4
8 The effect of assessment
on reduction of
uncertainty
1 Effect of technology
on reduction of
disease prevalence
and incidence
1 - - Economic
productivity
2 - - - -
9 Marginal benefits 1 Disease impacts 1 - - Financial
protection
1 - - - -
10 Ability to reduce own
health risk
1 Effect on targeted
groups
1 - - Subsidized
Payment
1 - -
11 Potential to extend life 1 Size of vulnerable
population
1 - - Society
interest and
demand
1 - - - -
12 Potential to detect a
condition which, if
treated early, averts costs
in the future
1 - - - - Technology
price and sale
volume
1 - - - -
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factors. Maximum frequency in health outcomes related to
health effects/benefits (8 studies), maximum frequency in
disease and target population was related to disease severity
(12 studies), maximum frequency in alternatives was related
to number of alternatives (2 studies), maximum frequency
in economic aspects was related to cost-effectiveness (15
studies), maximum frequency in evidence was related to
quality of evidence (4 studies) and in other factors, max
frequency was related to issues concerning the health
system (11 studies) (Table 1).
Phase 1: Content validity verification
Sub criteria obtained from the systematic review phase that
were classified into six dimensions were designed as three
questionnaires, including 54 sub criteria and one question
for extraction of extra criteria. To determine the content
validity of 11 health experts, technology assessment were
questioned in three ways: (a.) determination of face validity
for each item (as two-option: it is clear and demonstrative
or it is not clear and demonstrative), (b.) determination of
content validity ratio (CVR) for each item (as three-option:
it is necessary, useful but not necessary or not necessary)
and (c.) determination of content validity index (CVI) for
each item (as five-option: completely irrelevant, irrelevant,
relatively irrelevant, relevant or completely relevant). Firstly,
content validity index (CVI) was calculated for each item
such that out of 55 items, 21 items were obtained following
a minimum of 0.79 which included health benefits, clinical
impacts, efficacy/effectiveness, potential to increase the life,
safety, population size, the number of potential beneficiar-
ies, the impact on target groups, the size of vulnerable pop-
ulations, the availability of alternative technologies, cost-
effectiveness, costs, budget impact, financial protection, the
quality of evidence, number of evidence, the issues related
to the health system, the issues related to the availability of
expertise, equity in better access to health care and the
question of additional criteria. Shortly following this, con-
tent validity ratio was calculated for each item such that,
out of 54 sub criteria, all questioned experts had consensus
on the necessity of only 9 sub criteria (health benefits, clin-
ical benefits, efficacy/effectiveness, safety, cost-effectiveness,
costs, technology price, quality of the evidence and issues
related to rate availability of expertise) in this framework
and obtained a score higher than score of Lawshe table for
11 experts. Whereas, Lawshe clarified that each item with
more than half the total population of people had consen-
sus on its necessity, and had a level of content validity (to
the same rate of people that voted to its necessity) [9].
Thus, in addition to 9 sub criteria that had obtained the re-
quired score of CVR, a sub criteria greater than 50 % of
people (including 50 % itself and higher) voted to its neces-
sity and a CVI greater than 0.79 was obtained, kept and in-
cluded into the final questionnaire (for assessment of their
importance). These sub criteria were as follows: clinical
impacts, efficiency/effectiveness, individual health benefits,
safety, population size, number of potential beneficiaries, ef-
fect on targeted group, vulnerable population size, availabil-
ity of alternative technologies, quality of evidence, number
of evidence, budget impact, cost effectiveness, financial pro-
tection, issues related to health system and availability rate
of experience and specialty and additional question for
other criteria. Based on face validity, according to the
opinion of experts, 4 sub criteria including individual
health benefits, clinical impacts, efficiency/effective-
ness, and effect on targeted group due to their overlap
were all combined in the efficiency/effectiveness sub
criteria. In addition, in the same manner, sub criteria
of number of potential beneficiaries was combined
with the population size, costs combined with cost ef-
fectiveness while number of evidence was renamed as
the adequacy of the evidence. Thus, in the final ques-
tionnaire, 13 sub criteria were included based on 6
dimensions of conceptual model of study (Table 2).
Table 2 Sub criteria obtained after first phase of question from
experts
No. Criteria Sub criteria
Dimension
1
Health Outcomes Efficiency/Effectiveness, Safety
Dimension
2
Disease and target
population
Population Size, Vulnerable Population
Size
Dimension
3
Alternatives Availability of Alternative
Technologies
Dimension
4
Economic Aspects Budget Impact, Cost Effectiveness of
Technology in Other Countries,
Financial Protection
Dimension
5
Evidence Quality of Evidence, Adequacy
Number of Evidence
Dimension
6
Other criteria Issues Related to Health System, Issues
Related to Availability of Experience
and Specialty about Technology
and Issue Related to the Equity
Table 3 Final sub criteria obtained after two phases
questioning from experts
No. Criteria Sub criteria
Dimension
1
Health Outcomes Efficiency/Effectiveness, Safety
Dimension
2
Disease and target
population
Population Size, Vulnerable
Population Size
Dimension
3
Alternatives Availability of Alternative
Technologies
Dimension
4
Economic Aspects Budget Impact, Cost Effectiveness of
Technology in Other Countries,
Financial Protection
Dimension
5
Evidence Quality of evidence
Dimension
6
Other criteria -
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Phase 2: Determining importance of each sub criteria
Thirteen obtained sub criteria in previous phase were in-
cluded into the final questionnaire phase based on the
same process, 9 sub criteria, including Efficiency/effect-
iveness, safety, Population size, vulnerable population
size, availability of alternative technologies, budget Im-
pact, cost effectiveness of technology in other countries,
financial protection, quality of evidence that obtained a
greater than 75 % importance as viewpoint of questioned
experts, were included in the paired wise comparisons
questionnaire as the final 9 effective criteria in the prior-
ity setting of health technology assessment and this
finalized the extraction of relative weight (Table 3). To
assess the reliability of the final questionnaire, data ob-
tained from each sub criterion were entered into SPSS
software as Likert spectrum and the Cronbach’s alpha
was calculated with its value at 0.697. This demonstrated
an acceptable reliability of the final questionnaire.
Moreover, no consensus was made between questioned
experts in relation to the additional criteria individually
mentioned by the experts. These criteria include Ethical
issues, burden of disease, information value, the elasti-
city of demand for technology, procedures and methods
of diagnosis and treatment, the external dependence of
the use of technology, the development and application
of technology in the world and the indication of
technology.
Phase 3: Identification of relative weights of final criteria
Nine final effective criteria selected based on the opinion
of experts were designed during the first and second
phases as paired comparisons questionnaire and in an-
other case they were presented to nine questioned ex-
perts in the first and second phases (at this phase, two
experts of the previous phases were not available) in
order to extract the relative weight of each one of the 9
Table 4 Relative weight obtained from normalization of geometric mean of each row of final matrix
Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness in
other countries
Budget
impact
Financial
protection
Quality of
evidence
Relative
Weight
0.12 0.20 0.06 0.08 0.08 0.13 0.08 0.09 0.15
Table 5 Coding of efficiency/effectiveness criteria [10]
Quantitative
code
Status For Technologies Related to Treatment and Rehabilitation: Clinical
Benefit and Improvement of Quality of Life
5 Perfect treatment
4 Lifetime increasing and major improvement of quality of life
3 Lifetime increasing and low improvement of quality of life
2 Major improvement of quality of life
1 Low improvement of quality of life
Quantitative
code
Status For Technologies Related to Screening and Diagnosis: Accuracy
of Technology and Treatment Status of Disease under Screening
and Diagnosis
5 Technology accuracy was more than 80 % and disease under
screening and diagnosis may be treated.
4 Technology accuracy was within 60–80 % and disease under
screening and diagnosis may be treated.
3 Technology accuracy was over 80 % but the disease under
screening and diagnosis may not be treated.
2 Technology accuracy was within 60–80 % and disease under
screening and diagnosis may not be treated or accuracy was 60 %
and disease under screening and diagnosis may be treated.
1 Technology accuracy was less than 60 % and disease under
screening and diagnosis may be treated.
Quantitative
code
Status For Technologies Related to Prevention: Effectiveness of
Technology for Prevention of Disease
5 Over 90 %
4 81–90 %
3 71–80 %
2 61–70 %
1 Less or equal to 60 %
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final criteria. After filling the 9 questionnaires aforemen-
tioned, the information of these questionnaires was en-
tered into an excel sheet as 9 matrixes (9*9) and to
extract the final weight and equalizing the data of these
9 matrixes, a final matrix was formed such that in each
one of its entries was included the geometric mean of its
corresponding entries in 9 matrixes (9*9). The relative
weigh of each criterion was extracted from the final
formed matrix through normalization of geometric mean
of each line thereof. Later, the obtained inconsistency
ratio for the system was calculated, which was less than
the range of 0.1 (IR = 0.03) and demonstrated
consistency between extracted weights (Table 4).
Phase 4: Piloting the priority setting model
According to the inquiry from health technology assess-
ment department of ministry of health, and medical edu-
cation, 3 health technologies that were requested for
health technology assessment, were selected and TOP-
SIS priority setting pilot model was implemented on
them. These technologies included the following:
a. Adenosine
b. Tissue Plasminogen Activator (tPA)
c. Mechanical Thrombectomy
Furthermore, to fill the decision matrix for execution
of model pilot, values 1 to 5 were designed for each one
of 9 final criteria, and data related thereto were extracted
from available evidence for the three pilot technologies:
(Tables 5, 6, 7, 8, 9, 10, 11, 12 and 13).
The data obtained from evidence about three above-
mentioned technologies
Adenosine for the treatment of supraventricular
tachycardia [11] Status of efficiency/effectiveness cri-
teria: This medication with a dose of 12 mg quickly and
effectively terminated proximal episodes of the supra-
ventricular tachycardia (relative code = 5) [12]. Status of
safety criteria: The use of this medication resulted in a
slightly bad side effect such as confusion, nausea,
redness of face etc. (relative code = 4) [13]. Status of
population size criteria: Supraventricular tachycardia
prevalence was 2.25 cases in a general 1000-persons
population. Therefore, the size of target population of
this medication in Iran, considering its 80 million popu-
lation was about 180 thousand peoples (relative code =
4) [11]. Status of vulnerable population size criteria: The
probability of supraventriclar tachycardia in women was
2 times more than men, and majorly in pregnancy and
fertility ages (within 15–30 years) (relative code = 4) [11].
Status of alternative technologies availability criteria:
Verapamile is the alternative medication that has equal
efficiency and relatively equal safety and mostly available
in the health centers (relative code = 2) [11, 13]. Status
of quality of evidence criteria: Concerning this medica-
tion, there is a systematic review study of randomized
controlled studies of meta-analysis type with a high
quality (relative code = 5) [13]. Status of cost effective-
ness criteria: The data about this criterion was unspeci-
fied (relative code = 1). Status of budget impact criterion:
The data about this criterion was unspecified (relative
code = 1). Status of financial protection criterion: The data
about this criterion was unspecified (relative code = 1).
Tissue plasminogen activator (tPA) for the treatment
of stroke [14] Status of efficiency/effectiveness criteria:
The use of this medication resulted in a 0.07 increase of
lifetime together with 0.24 increase of QALY (relative
code = 3) [15]. Status of safety status: In comparison to
placebo, the use of this technology had higher risk of
intracranial hemorrhage (relative code = 3) [16]. Status
of population size criteria: prevalence of stroke in west
countries was about 12000 per million peoples [17]. The
prevalence and incidence of stroke in Iran was signifi-
cantly higher than western countries [18]. Thus, in
Iranian population, assuming 80 million people, the
population size under impact of this disease will be
higher than one million people (relative code = 5). Status
Table 6 Coding of Safety Criteria (as qualitative estimation or
using quantitative indicators available in the safety context):
Improvement rate in reduction of risk or incidence of side
effects arising out of utilization of technology in the target
population
Quantitative code Status
5 Completely safe (lack of side effects)
(Incidence of side effects less than 1 %)
4 Relatively safe (mild and slight side effects)
(Incidence of side effects between 1 to 9.9 %)
3 Proper safety (averagely side effects)
(Incidence of side effects between 10 to 39 %)
2 Poor safety (much side effects)
(Incidence of side effects 40 to 50 %)
1 Unsafe (major side effects)
(Incidence of side effects more than 50 %)
Table 7 Coding of population size criteria: number of people
under effect of disease or health problem that will be treated or
prevented by technology [10]
Quantitative code Status
5 More than 500000
4 100001 to 500000
3 50001 to 100000
2 10001 to 50000
1 Less or equal to 10000
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of vulnerable population size criteria: The incident of
stroke was mostly prevalent among Iranian women
(within 51–53 %) and majorly occurred within seventh
decade of life (relative code = 4) [19]. Status of alterna-
tive technologies availability criteria: This technology
was the first and the only effective therapeutic method
for patients with stroke 3 times after its first occurrence
(relative code = 5) [16]. Status of quality of evidence cri-
teria: In relation to this technology, there was a high
quality randomized multicenter controlled trial (elative
code = 3) [16]. Status of cost effectiveness criteria: The
incremental cost effectiveness ratio for all patients con-
suming this medication was about 6255 Dollars per
QALY. This value was obtained for USA. Considering
her per capital GDP in 2014 as equal to 53000$. This
value is rather highly cost effective (relative code = 5)
[15]. Status of budget impact criteria: The data in rela-
tion to this criterion was unspecified (relative code = 1).
Status of financial protection criteria: The data in rela-
tion to this criterion was unspecified (relative code = 1).
Mechanical thrombectomy for the treatment of
stroke [20] Status of efficiency/effectiveness criteria:
This technology resulted in a 0.68 increase of QALY (rela-
tive code = 1) [21]. Status of safety criteria: This technol-
ogy was safe which could demonstrate higher rate of
symptomatic bleeding than medicinal methods (relative
code = 3) [20]. Status of population size criteria: Preva-
lence of stroke in west countries was about 12000 per mil-
lion peoples [17]. The Prevalence and incidence of stroke
in Iran was significantly higher than western countries
[18]. Thus, in Iranian population, assuming 80 million
people, the population size under impact of this disease
will be higher than one million people (relative code = 5).
Status of vulnerable population size criteria: The incident
of stroke was mostly prevalent among Iranian women
(within 51–53 %) and majorly occurred within seventh
decade of life (relative code = 4) [19]. Status of alternative
technologies availability criteria: This method was the only
Table 8 Coding of vulnerable population criteria: share of
children below 5 years old or women in fertility ages or elders
over 65 years old or patients suffering from special diseases
(including MS, dialysis, hemophilia and thalassemia) or patients
suffering from neuropsychological diseases in the target
population
Quantitative code Status
5 More than 50 %
4 26–50 %
3 11–25 %
2 Less or equal to 10 %
1 Unspecified vulnerable population size
Table 9 Coding of Availability rate of Alternative technologies
(qualitative estimation): Availability of other alternative methods
for technology in target population
Quantitative
code
Status
5 Partial availability of alternative technologies
with the same safety and effectiveness for
target population
4 Relatively appropriate availability of alternative
technologies with the same safety and effectiveness
for target population
3 Appropriate availability of alternative technologies
with the same safety and effectiveness for
target population
2 High availability of alternative technologies
with the same safety and effectiveness for
target population
1 Very high availability of alternative technologies with
the same safety and effectiveness for target population
Table 10 Coding of quality of evidence: quality of evidences of
health technology assessment, systematic review and clinical
trials on technology
Quantitative
code
Status
5 Systematic reviews with high quality of randomized
controlled trials or heath technology assessment with
high quality therein systematic review has been
performed (based on checklist of CASP and INAHTA)
4 Systematic reviews with medium or low quality of
randomized controlled trials or heath technology
assessment with medium or low quality therein
systematic review has been performed (based on
checklist of CASP and INAHTA)
3 Randomized controlled trials or clinical controlled trials
with high quality or systematic review with high quality
of other studies (based on CASP checklist)
2 Randomized controlled trials or clinical controlled trials
with medium or low quality or systematic review with
medium or low quality of other studies or cohort
studies with any kind of quality (based on CASP
checklist)
1 Other studies (cohort, case series and quasi-random
studies etc.) with any quality
Table 11 Coding of cost effectiveness: status of cost
effectiveness of technology in other countries
Quantitative
code
Status
5 very cost effective (cost per QALY lower than 1 time
more than per capital GDP)
4 Reasonable cost effective (cost for QALY within 1–2
times more than per capital GDP)
3 Slightly cost effective (cost for QALY within 2–3 times
more than per capital GDP)
2 Not-cost effective (cost for QALY more than 3 times
more than per capital GDP)
1 Unspecified cost effectiveness status
Mobinizadeh et al. DARU Journal of Pharmaceutical Sciences  (2016) 24:10 Page 8 of 12
therapeutic method for patients with incident of stroke
who were not treated by clot solving medications, since
the use of this method resulted in failure with respect to
them (during first 3–4 h after this occurrence) (relative
code = 5) [20]. Status of quality of evidence criteria: In re-
lation to this technology, there was health technology re-
port from randomized r controlled trial with high quality
(elative code = 5) [20]. Status of cost effectiveness criteria:
The incremental cost effectiveness ratio for all patients
taking this medication was about 16000 Dollars per
QALY. This value was obtained for USA and considering
per capital GDP of this country in 2014, which equaled
53000$, this value is rather highly cost effective (relative
code = 5) [21]. Status of budget impact criteria: The data
in relation to this criteria was unspecified (relative code =
1). Status of financial protection criterion: The data in re-
lation to this criterion was unspecified (relative code = 1).
Final TOPSIS pilot model
Finally TOPSIS pilot model was designed by 3 health
technologies and relative weights. The results showed
that tissue plasminogen activator treatment was the first
priority, adenosine was second and mechanical thromb-
ectomy was third in performing health technology as-
sessment by Iranian ministry of health and medical
education (Table 14). Finally, the pilot model was pre-
sented to an internal panel which was made up of 6
experts of health technology assessment and was
approved.
Discussion
Generally, this study which was applied based on the
combined model of analytic hierarchy process and TOP-
SIS, was presented for the first time in the world, in the
health technology assessment priority setting context.
The differences and similarities between this model and
main model of Canadian Agency for Drugs and Tech-
nologies in Health are explained in terms of finalized cri-
teria in this model. The criteria used in this model
which extracted using a systematic review which in-
cluded a number of alternatives and access such as,
budget impact, clinical impact, controversial nature of
technology, disease burden, economic impact, moral and
legal issues, quality and level of evidences, expected level
of interests, time period of assessment and its effect on
health and clinical medicine policies, variety in direction
for use and application of technology. The criteria used
in the model of this study included efficiency/effective-
ness, safety, population size, vulnerable population size,
availability of alternative technologies, cost effectiveness
in other countries, budget impact, financial protection,
and quality of evidences. Efficiency/effectiveness, avail-
ability of alternative technologies, quality of evidences
and budget impact as common items and controversial
nature of technology, disease burden, economic impact,
moral and legal issues, expected level of interests, time
period of assessment and its effect on health and clinical
medicine policies, variety in direction for use and appli-
cation of technology in Canadian model and safety,
population size, vulnerable population size, cost effect-
iveness in other countries and financial protection in the
model of this study were assumed as differences. In rela-
tion to multi criteria decision making model used in this
study, it is noteworthy that in Canadian model, overall
relative weight extraction, as well as, final priority setting
were performed based on analytic hierarchy process,
whilst in the model of this study, only relative weight
was extracted for determination of exact weight using
final purpose which implied that, health technology as-
sessment priority setting in Iran, through paired compar-
isons and no judgment of experts, were applied on the
final model. This subject was designed in order to ad-
here to evidence based medicine (EBM) and its evidence
pyramid using TOPSIS model and ascertain the use of
codes extracted from evidence related to the technology,
which can prevent the fully and unlimited interventions
of medical beneficiary groups for selection of health
technologies that are assumed as the stewardship scope.
In fact, out of 11 criteria acquired from systematic re-
view phase of Canadian model and mentioned earlier, 6
criteria including disease burden, clinical impact, alter-
native technologies, budget impact, economic impact
and available evidence were selected as the main criteria
by health technology assessment experts of that country.
Table 12 Coding of budget impact (as qualitative estimation):
net impact of covering the technology on the budget of health
system
Quantitative
code
Status
5 Significant savings
4 Moderate savings
3 Very slight change in the amount of savings
2 No significant changes in the costs or additional
charges
1 Unspecified budget impact status
Table 13 Coding of financial protection: the probability that
the technology covered by the basic health insurance package
and thus prevent the occurrence of catastrophic health
expenditures
Quantitative code Status
5 100 %
4 76 to 99 %
3 50 to 75 %
2 Less than 50 %
1 Unspecified financial protection status
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In relation to weight extraction phase, the following
values were obtained: disease burden (0.216), clinical im-
pact (0.258), alternative technologies (0.081), budget im-
pact (0.143), economic impact (0.167), and available
evidence (0.135) [4]. Furthermore, these values were
comparable with the values obtained from the present,
study including efficiency/effectiveness (0.12), safety
(0.2), population size (0.06), vulnerable population size
(0.08), availability of alternative technologies (0.08), cost
effectiveness in other countries (0.13), budget impact
(0.08), financial protection (0.09), and quality of evidence
(0.15). The model designed in this study may also be
compared to the health technology assessment priority
setting model in Latvia. In this model, research of
Table 14 Final TOPSIS pilot model
Decision Matrix
Criteria Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
Technology
Adenosine 5 4 4 4 2 1 1 1 5
Tissue
Plasminogen
Activator
3 3 5 4 5 5 1 1 3
Mechanical
Thrombectomy
1 3 5 4 5 5 1 1 5
Weight Matrix
Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
RelativeWeight 0.12 0.20 0.06 0.08 0.08 0.13 0.08 0.09 0.15
Norm Matrix
Criteria Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
Technology
Adenosine 0.85 0.69 0.49 0.58 0.27 0.14 0.58 0.58 0.65
Tissue
Plasminogen
Activator
0.51 0.51 0.62 0.58 0.68 0.70 0.58 0.58 0.39
Mechanical
Thrombectomy
0.17 0.51 0.62 0.58 0.68 0.70 0.58 0.58 0.65
V Matrix
Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
Adenosine 0.11 0.14 0.03 0.05 0.02 0.02 0.05 0.05 0.10
Tissue
Plasminogen
Activator
0.06 0.10 0.04 0.05 0.05 0.09 0.05 0.05 0.06
Mechanical
Thrombectomy
0.02 0.10 0.04 0.05 0.05 0.09 0.05 0.05 0.10
Positive Ideal
Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
A+ 0.11 0.14 0.04 0.05 0.05 0.09 0.05 0.05 0.10
Negative Ideal
Efficiency/
effectiveness
Safety Population
size
Vulnerable
population
Availability rate of
alternative technologies
Cost effectiveness
in other countries
Budget
impact
Financial
protection
Quality of
evidence
A- 0.02 0.10 0.03 0.05 0.02 0.02 0.05 0.05 0.06
Final Priority Setting
d1+ 0.08 d1- 0.10 closeness1 0.56 2
d2+ 0.07 d2- 0.09 closeness2 0.57 1
d3+ 0.09 d3- 0.09 closeness3 0.49 3
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literature review as well as qualitative study was used in
the model design, followed by a test for health technol-
ogy assessment priority setting. To test the model and
method, 3 round Delphi model was implemented using
electronic questionnaire. Accordingly, Delphi technique
was invented as a method for making consensus in the
health technology assessment priority setting for Latvia.
Criteria affecting this model included health benefit, evi-
dence, assessment scheduling, expected level of policy
makers’ benefits, social, legal and moral concepts [22].
Two criteria of health benefit and evidence were com-
mon criteria in the model designed in the present study.
The designed model of this study may be compared to
the health technology assessment priority setting model
in Netherlands. In this model, various methods were
used for classification, scoring and weighting the policy
making criteria, including actual disease burden, poten-
tial health benefit, number of patients, direct interven-
tion costs for each patient, financial consequences of
intervention implementation over time and its impact
on the health system policies [23]. Three criteria, includ-
ing health benefit, number of patients and financial con-
sequences were assumed as the three common criteria
in the model designed for this study. Overall, the model
designed in the present study in comparison to previous
models in this context had innovation in the light of ef-
fective criteria because of its additional safety, vulnerable
population size, cost effectiveness of technology in other
countries and financial protection to the previous
models. In addition, as mentioned before, technically
this is the first time that a combined model of analytic
hierarchy process and TOPSIS has been used in this
relation.
Conclusion
According to the results of this study, this model with
nine effective criteria and their relative weights and in
combination with TOPSIS approach could be used with
suitable applicability by health technology assessment
department in deputy of curative affairs and food and
drug organization for determination of research prior-
ities in health technology assessment. Considering the
increasing growth of health technologies, ministry of
health and medical education, using this model, can allo-
cate its research budgets to health technologies assess-
ment which are of priority and importance to the health
system and society. It may promote the final impact of
health technology assessment reports on the macro
health policies and optimize the allocation of financial
resources of health sector.
Limitations
This model is not applicable for prioritization of orphan
drugs.
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